contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


zealand-pharma-announces-closing-of-collaboration-and-license-agreement-with-roche

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Zealand Pharma är verksamt inom bioteknik. Särskilt fokus återfinns inom utvecklingen av läkemedel för behandling av diabetes och diverse tarmsjukdomar. Bolaget innehar en varierad produktportfölj med separata varumärken som säljs på global nivå. Störst verksamhet finns inom den nordiska marknaden. Zealand Pharma grundades 1997 och har sitt huvudkontor i Söborg, Danmark.

Zealand Pharma

Company announcement – No. 12 / 2025 Zealand Pharma announces closing of collaboration and license agreement with Roche Copenhagen, Denmark, May 9, 2025 – Zealand Pharma A/S ("the Company" or...

Company announcement – No. 12 / 2025 Zealand Pharma announces closing of collaboration and license agreement with Roche Copenhagen, Denmark, May 9, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces that all closing conditions in the collaboration and license agreement with Roche <a href="https://www.globenewswire.com/Tracker?data=NJ3VrsyzuTXVQsHn5h0bs6ldcFERro6sstIJeut_ldDMZzX8gGOhG70R-Tr6BnLiXvDH32M7fDrLElWQ-gf_SYD3__SioxJYnFbxepK2e3YcQ8uW6r5K0XeFAncsdu0PBLakI1WdXcbVwth2ZE3bntOFLCSnP8INCFcmwEo4oPZBKFKaEUEiuyeUBfIjXOAGub7oOKcs7zHOE-SzITIutX68SUbutwXfhvLMu5frBdnD6V2ADB5L8-12-39H8fJ1ZqiIRP8sSsDGZ2-7rZ8w6SbJWq8dE8ZpvREHrfiX6stVftKPIIhU7WUO9u89cEhddkq2bmgkC_Ry_pX2tvo8Kk1693N6EpYdqbvDjEo4szoJM8ZZmE6zWb2e608iramMZRAfQY039O2lbIzDMIg3SGEQet4SkPBhv991nAATv5I=">announced on March 12, 2025</a> have been satisfied, including regulatory conditions, and the agreement has become effective. “We are incredibly excited to launch this partnership, which represents a step change to realize Zealand Pharma’s vision of becoming a key player in the future management of obesity. Roche ticked all the right boxes for what we were looking for in a partner and we look very much forward to working closely together to unlock the full potential of petrelintide to benefit people who are overweight or obese”, said Adam Steensberg, Chief Executive Officer at Zealand Pharma.&nbsp; # # # About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products. Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the United States. For more information about Zealand’s business and activities, please visit <a href="https://www.globenewswire.com/Tracker?data=lDm55OjEyZIRDAhcq1aLx_jpr0fIs_JwILFDn1n6-UphRpfKv4RE4J82MZGhUT8mfuAoGdjIq9Cc7fsr_w3-RTVFqa7KGJWo3sm51Ud_03U=">www.zealandpharma.com</a>. Contacts Adam Lange (Investors) Vice President, Investor Relations Zealand Pharma Email: <a href="https://www.globenewswire.com/Tracker?data=4mcOomR6uDJFFgWX8uw_SYCO--fI6AYRiHkzQEdbVR2RSaWWIse4XcdY3HHtB6zUdasVmKpA2VCFZSoXHcpZ-xkPFqpNJ2xRFQoZeEQImA6askJAAkUaO8k0a9H6IPIT">alange@zealandpharma.com</a> Neshat Ahmadi (Investors) Investor Relations Manager Zealand Pharma Email: <a href="https://www.globenewswire.com/Tracker?data=NdoyTg6J7YO7ehnTpHC7AzPqTR-i801Gc3baa0z2b0MmCy2fmd5MGxvc6C7H3ATxClNqEl_OOiegoMYbg8Aetet2cBnCr7T6mxU0F8a7ql4KqajcLRMrb-1mfq1lYG_t">neahmadi@zealandpharma.com</a> Anna Krassowska, PhD (Investors and Media) Vice President, Investor Relations &amp; Corporate Communications Zealand Pharma Email:&nbsp;<a href="https://www.globenewswire.com/Tracker?data=URQv2pxe6oLVrvMEjWPfUvCIDQt3pEeeXNm36i5uaZ2i3vR-PXdEtT-KUkWtVbWUJLsppBwsADeya0ZcuaSAui7GaU8wopC-4UWhVLQ6I6vfe2OskUOkWBvuzdyAakt-yDJOyYlgBNpnrcWZiOIHYLht3zItePt4f9ILzhb3drYaHQ-TIadU2YR2FWXP0diudwMwYlNXNwHamVBchiIkMPqow82TVgVLOUZeEl7a7PPs3xQq06AYklIrWe3JVMwxrt3hJJq_Cj_IqmqYLgDayNnX54du8BcXvG72ZuSRSAKQx3w-xSmSypWoaW1GDnzE">akrassowska@zealandpharma.com</a> <img src="https://www.globenewswire.com/newsroom/ti?nf=MTAwMTA5NTU2OSM0MDIxMzg1MDUjMjAwMTcwMQ==" alt=""> <img src="https://ml-eu.globenewswire.com/media/OTUyZjY1NGQtMTY0NS00NDNiLTk0ZWItODM0NjZjY2Q4YTY5LTEwMTMyNzQtMjAyNS0wNS0wOS1lbg==/tiny/Zealand-Pharma.png" alt="">

Zealand Pharma announces closing of collaboration and license agreement with Roche

USA:s Black Week ledde till överraskande inköp

Uppgångsvecka bakom oss, Tyskland gick vidare med sin megabudget

Finlands ekonomiska tillväxt: ”Varje dag och varje natt tänker jag på dig”

Nedgångsvecka bakom oss, AI-oron når även obligationsmarknaden

USA:s sysselsättningssiffror: En ljusglimt i Feds fyr